Aclaris Therapeutics (ACRS) Revenue (2017 - 2026)

Aclaris Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Revenue rose 37.18% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $8.4 million (down 52.94% YoY), while the FY2025 annual figure was $7.8 million, down 58.19% from the prior year.
• Revenue was $2.0 million for Q1 2026 at Aclaris Therapeutics, up from $1.3 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $19.0 million in Q3 2022 to a low of $1.3 million in Q4 2025.
• Historically, Revenue has averaged $5.3 million across 5 years, with a median of $2.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Revenue soared 1046.35% in 2022, then slumped 85.94% in 2025.
• A 5-year view of Revenue shows it stood at $7.8 million in 2022, then surged by 126.62% to $17.6 million in 2023, then sank by 47.58% to $9.2 million in 2024, then plunged by 85.94% to $1.3 million in 2025, then jumped by 54.13% to $2.0 million in 2026.
• The last three Revenue figures came in at $2.0 million (Q1 2026), $1.3 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.